Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity

被引：1

作者：

Della-Morte, David ^{[1
,2
]}

Riondino, Silvia ^{[1
,2
]}

Ferroni, Patrizia ^{[2
]}

Palmirotta, Raffaele ^{[2
]}

Pastore, Donatella ^{[1
]}

Lauro, Davide ^{[1
]}

Guadagni, Fiorella ^{[2
]}

Roselli, Mario ^{[1
]}

机构：

[1] Univ Roma Tor Vergata, Dept Syst Med, Sch Med, I-00133 Rome, Italy

[2] IRCCS San Raffaele Pisana Res Ctr, Biomarker Discovery & Adv Technol BioDAT Lab, Rome, Italy

来源：

PHARMACOGENOMICS | 2015年 / 16卷 / 01期

关键词：

angiogenesis; cancer; elderly; genetics; single nucleotide polymorphisms; tumor prognosis; vascular endothelial growth factors; VEGF; VEGF inhibitors; ENDOTHELIAL-GROWTH-FACTOR; RENAL-CELL CARCINOMA; METASTATIC COLORECTAL-CANCER; SINGLE NUCLEOTIDE POLYMORPHISMS; GENDER-SPECIFIC ASSOCIATION; BEVACIZUMAB-BASED THERAPY; ADVANCED BREAST-CANCER; LUNG-CANCER; PROSTATE-CANCER; TUMOR ANGIOGENESIS;

D O I：

10.2217/PGS.14.136

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Vascular endothelial growth factors (VEGFs) are the key regulators in angiogenesis and have been shown to play a significant role in the progression and prognosis of angiogenesis-related diseases, such as cancer. VEGF inhibitors are a current pharmacological antitumoral strategy. However, despite the strong association between aging and cancer incidence and progression, recent findings suggest impaired angiogenesis accompanied by a reduced expression of VEGF in cells derived from aging subjects. Specific variations of VEGF genes have been demonstrated to be genetic determinants for susceptibility, outcome and therapy response, especially for the solid tumors. Considering the complications present in frail elderly patients, analysis of VEGF genetic polymorphisms in these subjects may further help in tailoring an antiangiogenic pharmacological strategy, and in improving our ability to better understand prognosis during therapy-related to cancer.

引用

页码：61 / 78

页数：18

共 50 条

[21] VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
Scartozzi, Mario
Faloppi, Luca
Baroni, Gianluca Svegliati
Loretelli, Cristian
Piscaglia, Fabio
Iavarone, Massimo
Toniutto, Pierluigi
Fava, Giammarco
De Minicis, Samuele
Mandolesi, Alessandra
Bianconi, Maristella
Giampieri, Riccardo
Granito, Alessandro
Facchetti, Floriana
Bitetto, Davide
Marinelli, Sara
Venerandi, Laura
Vavassori, Sara
Gemini, Stefano
D'Errico, Antonietta
Colombo, Massimo
Bolondi, Luigi
Bearzi, Italo
Benedetti, Antonio
Cascinu, Stefano
INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (05) : 1247 - 1256
[22] The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer
Sung Yong Oh
Hyuk-Chan Kwon
Sung Hyun Kim
Suee Lee
Ji Hyun Lee
Jung-Ah Hwang
Seung Hyun Hong
Christian A Graves
Kevin Camphausen
Hyo-Jin Kim
Yeon-Su Lee
BMC Cancer, 13
[23] Significant Associations of Mismatch Repair Gene Polymorphisms With Clinical Outcome of Pancreatic Cancer
Dong, Xiaoqun
Jiao, Li
Li, Yanan
Evans, Douglas B.
Wang, Huamin
Hess, Kenneth R.
Abbruzzese, James L.
Li, Donghui
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1592 - 1599
[24] Association of VEGF-A genetic polymorphisms with cancer risk and survival in advanced-stage oral squamous cell carcinoma patients
Supic, Gordana
Jovic, Nebojsa
Zeljic, Katarina
Kozomara, Ruzica
Magic, Zvonko
ORAL ONCOLOGY, 2012, 48 (11) : 1171 - 1177
[25] VEGF gene polymorphisms in Iranian patients with intracranial glioblastoma
Hanaei, Sara
Mojtahedi, Hanieh
Namvar, Mohamad
Iranmehr, Arad
Safaei, Reyhaneh
Razavi, Azadehsadat
Esmaeili, Marzie
Sadr, Maryam
Rezaei, Arezou
Edalatfar, Maryam
Kashani, Hamidreza K. H. A. Y. A. T.
Sadeghi-naini, Mohs en
Darbeheshti, Farzaneh
Gharehdaghi, Jaber
Forouzesh, Mehdi
Ebrahimi, Abdolali
Rezaei, Nima
JOURNAL OF NEUROSURGICAL SCIENCES, 2024, 68 (05) : 583 - 589
[26] VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
M Scartozzi
M Bianconi
L Faloppi
C Loretelli
A Bittoni
M Del Prete
R Giampieri
E Maccaroni
S Nicoletti
L Burattini
D Minardi
G Muzzonigro
R Montironi
S Cascinu
British Journal of Cancer, 2013, 108 : 1126 - 1132
[27] Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab
Koutras, A. K.
Antonacopoulou, A. G.
Eleftheraki, A. G.
Dimitrakopoulos, F-I
Koumarianou, A.
Varthalitis, I.
Fostira, F.
Sgouros, J.
Briasoulis, E.
Bournakis, E.
Bafaloukos, D.
Bompolaki, I.
Galani, E.
Kalogeras, K. T.
Pectasides, D.
Fountzilas, G.
Kalofonos, H. P.
PHARMACOGENOMICS JOURNAL, 2012, 12 (06) : 468 - 475
[28] Impact of robotics on the outcome of elderly patients with endometrial cancer
Lavoue, Vincent
Zeng, Xing
Lau, Susie
Press, Joshua Z.
Abitbol, Jeremie
Gotlieb, Raphael
How, Jeffrey
Wang, Yifan
Gotlieb, Walter H.
GYNECOLOGIC ONCOLOGY, 2014, 133 (03) : 556 - 562
[29] Can we avoid the toxicity of chemotherapy in elderly cancer patients?
Feliu, Jaime
Heredia-Soto, Victoria
Girones, Regina
Jimenez-Munarriz, Beatriz
Saldana, Juana
Guillen-Ponce, Carmen
Molina-Garrido, M. J.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 131 : 16 - 23
[30] The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib
Zheng, You-Bing
Zhan, Mei-Xiao
Zhao, Wei
Liu, Bing
Huang, Jian-Wen
He, Xu
Fu, Si-Rui
Zhao, Yan
Li, Yong
Hu, Bao-Shan
Lu, Li-Gong
MEDICAL ONCOLOGY, 2014, 31 (10) : 1 - 8

← 1 2 3 4 5 →